A group of researchers led by a physician from Memorial Sloan Kettering Cancer Center in New York City examined the natural history and growth kinetics of low-risk papillary thyroid cancer (PTC), defined as intrathyroidal tumors ≤1.5 cm in size.
A group of researchers led by a physician from Memorial Sloan Kettering Cancer Center in New York City examined the natural history and growth kinetics of low-risk papillary thyroid cancer (PTC), defined as intrathyroidal tumors ≤1.5 cm in size.
Active surveillance of low-risk PTC is an alternative to surgical removal. However, outcomes have not been fully studied.
In addition, the kinetics (probability, rate, and magnitude) of PTC tumor growth in patients who do not undergo surgery and are followed-up long-term have not been well defined.
In this cohort study of 291 patients undergoing active surveillance for low-risk PTC, 219 (75.3%) were women and the mean age of the group was 52 years.
During a median active surveillance of 25 months, growth in tumor diameter of 3 mm or more was observed in 11 of 291 (3.8%) patients. No regional or distant metastases developed during active surveillance.
Both younger age at diagnosis and a higher risk category at presentation were independently associated with the likelihood of tumor growth. Of the tumors that grew, kinetics demonstrated a classic exponential growth pattern, with a median doubling time of 2.2 years.
The researchers concluded that tumor volume kinetics can inform the timing of surveillance imaging for PTC. Study findings are available here.
FDA Approves T-DXd for Previously Treated HER2-Low and -Ultralow Metastatic Breast Cancer
Published: January 27th 2025 | Updated: January 28th 2025T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in patients whose disease progressed on prior endocrine therapy in the metastatic setting.
ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer
January 26th 2025While ctDNA positivity was linked to worse overall disease-free survival (DFS) in stage III resected colon cancer, it was associated with significantly improved DFS with celecoxib compared to placebo.